# GHK Peptide Dosage in the Research Literature — Dr GHK-Cu

> GHK peptide dosage in published studies ranges from 10^-12 M in fibroblast culture to 15 mg/kg intranasal in aged mice. Research-context only — all administration documented by species, route, and dose.

GHK peptide dosage in published research spans nine orders of magnitude across five administration routes — from picomolar cell culture concentrations to milligram-per-kilogram intranasal doses in aged mouse models. This page documents the administration context from the peer-reviewed literature. GHK-Cu is not an FDA-approved drug. All dosing information below describes what was administered in specific research models, not a recommendation for any use in humans.

## GHK-Cu Administration Routes in Published Research

Published studies have employed five distinct routes of administration for GHK-Cu:

**Topical cream/serum (human clinical trials):** The most clinically documented route. Concentrations from 0.01% to 1% GHK-Cu in topical formulations. The 12-week human trial used a topical cream at an unspecified concentration [2]. The nanolipid carrier study achieved 55.8% wrinkle volume reduction using this route over 8 weeks [5]. Skin penetration data confirm therapeutically relevant dermal accumulation: permeability coefficient 2.43 x 10^-4 cm/h, stratum corneum accumulation 438-fold over baseline [6].

**Intranasal (mouse cognitive studies):** 15 mg/kg daily (containing 2.1 mg/kg copper component) in 20-month-old aged mice [7]; 15 mg/kg three times weekly for 12 weeks in 5xFAD Alzheimer's model mice [18]. This route achieved CNS-accessible effects without validated systemic pharmacokinetics.

**Intraperitoneal (mouse pulmonary and inflammation studies):** 2.6, 26, and 260 μg/mL/day in the bleomycin pulmonary fibrosis model [11]; 0.2, 2, and 20 μg/g/day on alternate days in the cigarette smoke emphysema model [12]; 2 and 20 mg/kg in the silicosis model [20].

**Scaffold surface coating (in vitro tissue engineering):** 1 mM GHK-Cu coating on poly(ε-caprolactone)/collagen/chitosan scaffolds improved fibroblast viability and demonstrated antibacterial activity versus E. coli and S. aureus within 1 hour [21].

**Liposomal formulation (topical, enhanced delivery):** GHK-Cu liposomes applied topically to scald wounds in mice accelerated healing by day 14 post-injury and increased endothelial proliferation by 33.1% over free GHK-Cu [15].

## GHK-Cu Concentration Ranges in Published Skin Research

Topical formulation studies used concentrations ranging from 0.01% to 1% GHK-Cu in cream and serum vehicles. In vitro cell culture experiments used picomolar to micromolar concentrations to observe fibroblast response — maximum collagen stimulation at 10^-9 M (1 nanomolar), with detectable stimulation beginning at 10^-12 M (1 picomolar) [1]. The GHK/5-aminolevulinic acid hair growth trial used 50–100 mg/mL in topical formulation over 6 months [10]. Human mesenchymal stem cell cultures used 1–500 ng/mL GHK in medium (no cytotoxicity across this range) [16]. The GHK-Cu eye cream achieving wrinkle depth reduction was in the 0.01–1% range for topical use [5].

## GHK-Cu Half-Life and Pharmacokinetic Data

Precise plasma half-life data for systemically administered GHK-Cu in animal models is limited in the published literature. No validated pharmacokinetic parameters (T1/2, Cmax, AUC) for injectable or systemic routes have been published in peer-reviewed sources. Topical penetration studies provide the most quantitative PK-adjacent data: in human ex vivo skin, the stratum corneum forms a depot with gradual release into the dermis — a sustained 48-hour permeation profile [6]. For the intranasal route, two preprint studies document efficacy in mouse models at 15 mg/kg but do not report plasma concentration-time profiles [7][18]. The absence of validated systemic PK data is a recognized gap in the current GHK-Cu literature.

## Frequency in GHK-Cu Research Protocols

Published research protocols vary considerably by model and objective. Most human-applied studies used once or twice-daily topical application for 8–12 weeks [2][5]. The 6-month hair growth trial also used daily topical application [10]. Systemic injection studies in rodent pulmonary models used alternate-day intraperitoneal administration [12]. The intranasal cognitive studies used either daily administration [7] or three times weekly [18]. No published human study has formally characterized dose frequency response for GHK-Cu at any systemic route.

## Formulation and Stability Considerations

GHK-Cu has unfavorable physicochemical properties for passive skin penetration: MW 403.9 Da as the copper complex, clogP -2.24 (hydrophilic) [5]. Palmitoylation (Pal-GHK) and liposomal encapsulation improve dermal delivery. Formulation chemistry studies indicate strong acid actives (AHAs, BHAs) and ascorbic acid may reduce copper peptide stability in solution by competing for copper coordination — the clinical significance of these interactions in topical use is not fully established in randomized trials. Copper complexation itself enhances stratum corneum permeability relative to the free GHK tripeptide.

A 2025 review identified a critical measurement gap in liposomal GHK-Cu delivery: the mechanism of transport through skin for encapsulated versus free peptide remains incompletely characterized, and proposed CE-ICP-MS/MS methodology and Strat-M synthetic skin models as validated approaches for future studies [22].

## GHK-Cu Formulation Incompatibilities Noted in Research

Formulation chemistry studies indicate strong acid actives and ascorbic acid may reduce copper peptide stability in solution; copper peptide integrity in formulation may be reduced by AHAs, BHAs, and vitamin C. The clinical significance of these interactions in topical use is not fully established in peer-reviewed randomized controlled trials. These observations come from cosmetic chemistry literature and the stability section of the 2024 comprehensive review [5]. No dedicated incompatibility RCTs have been conducted.

## Human Clinical Data Summary

Human data is limited to topical dermatological studies. The most cited: a 12-week collagen density study (70% improvement in treated subjects) [2]; a 12-week eye cream study in 41 women with improved skin density and reduced wrinkles [5]; an 8-week nanolipid carrier study achieving 55.8% wrinkle volume reduction [5]; and a 6-month hair growth pilot with the GHK/5-ALA combination (71.5-hair gain at 50 mg/mL versus 9.6 in placebo) [10]. No published randomized controlled trials for systemic injection in humans. No completed Phase 2/3 trials registered for GHK-Cu as a drug. Topical studies up to 12 weeks report good tolerability. Long-term systemic safety in humans has not been formally studied.


## References

[1] Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. https://pubmed.ncbi.nlm.nih.gov/3169264/
[2] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[5] Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2024;14:30071. https://pmc.ncbi.nlm.nih.gov/articles/PMC11830136/
[6] Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research. 2010;59(11):983-988. https://pmc.ncbi.nlm.nih.gov/articles/PMC3016279/
[7] Tucker M, Keely A, Park JY, Rosenfeld M, Wezeman J, Mangalindan R, Ratner D, Ladiges W. Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. bioRxiv (preprint). 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10680828/
[10] Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Annals of Dermatology. 2016;28(4):438-443. https://pmc.ncbi.nlm.nih.gov/articles/PMC4969472/
[11] Zhou XM, et al. GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFbeta1/Smad-Mediated Epithelial-to-Mesenchymal Transition. Frontiers in Pharmacology. 2017;8:904. https://pmc.ncbi.nlm.nih.gov/articles/PMC5733019/
[12] Zhang Q, Yan L, Lu J, Zhou X. Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Frontiers in Molecular Biosciences. 2022;9:925700. https://pmc.ncbi.nlm.nih.gov/articles/PMC9354777/
[15] Wang X, Liu B, Xu Q, Sun H, Shi M, Wang D, Guo M, Yu J, Zhao C, Feng B. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair and Regeneration. 2017;25(2):229-239. https://pubmed.ncbi.nlm.nih.gov/28370978/
[16] Jose S, Hughbanks ML, Binder BYK, Ingavle GC, Leach JK. Enhanced trophic factor secretion by mesenchymal stem/stromal cells with Glycine-Histidine-Lysine (GHK)-modified alginate hydrogels. Acta Biomaterialia. 2014;10(5):1955-1964. https://pmc.ncbi.nlm.nih.gov/articles/PMC3976757/
[18] Tucker M, Liao GY, Park JY, Rosenfeld M, Wezeman J, Mangalindan R, Ratner D, Darvas M, Ladiges W. Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide. bioRxiv (preprint). 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10690187/
[20] Bian Y, Deng M, Liu J, et al. The glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biology. 2024;74:103237. https://pmc.ncbi.nlm.nih.gov/articles/PMC11228880/
[21] Molavi AM, Sadeghi-Avalshahr A, Nokhasteh S, Naderi-Meshkin H. Enhanced biological properties of collagen/chitosan-coated poly(epsilon-caprolactone) scaffold by surface modification with GHK-Cu peptide and 58S bioglass. Progress in Biomaterials. 2020;9(1-2):35-46. https://pmc.ncbi.nlm.nih.gov/articles/PMC7289912/
[22] Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Molecules. 2025;30(1):136. https://pmc.ncbi.nlm.nih.gov/articles/PMC11721469/

---

A 16-bit field guide to the copper peptide GHK literature — every study indexed, every stat cited, no coins spent on a clinic.